...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging
【24h】

Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging

机译:基于有效的多柔比星的纳米治疗,用于同时恶性淋巴瘤治疗和淋巴瘤生长影像

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In this study, we report the in vivo anti-lymphoma efficacy and diagnostic potential of newly designed near-infrared fluorescent dye containing polymer-doxorubicin conjugates using murine models of malignant lymphomas including one cell line-derived xenograft (RAJI) and two patient-derived lymphoma xenografts (VFN-D1 and VFN-M2). Two types of passively targeted conjugates differing in architecture of the polymer backbone were synthesized. One of the conjugates was designed using a single linear polymer chain, and the second was more sophisticated with a star-shaped high-molecular-weight (HMW) polymer employing a dendrimer core. The linear HPMA copolymers were linked to the dendrimer core via a one-point attachment, thus forming a hydrophilic polymer shell. Both polymer-doxorubicin conjugates were long-circulating with reduced side effects. Both polymer prodrugs were designed as stimuli-sensitive systems in which the anti-cancer drug doxorubicin was attached to the hydrophilic copolymers via a pH-labile hydrazone linkage. Such polymer prodrugs were fairly stable in aqueous solutions at pH 7.4, and the drug was readily released in mildly acid environments at pH 5-6.5 by hydrolysis of the hydrazone bonds. In addition, polymers were labelled with near-infrared fluorescent dye enabling long term in vivo visualization. Malignant lymphomas represent the most common type of haematological malignancies. Therapy for the majority of malignant lymphomas consists of multi-agent chemotherapy based on an anthracycline doxorubicin, the most prominent side effect of which is cardiotoxicity. We have demonstrated significant anti-lymphoma efficacy of the polymer-doxorubicin conjugates when compared to equally toxic doses of conventional (unbound) doxorubicin in all tested models. Favourable pharmacokinetics for carried drug and labelled polymer carrier was observed, showing predominant uptake of the drug and polymer itself in the tumour mass. In addition, we have observed a promising
机译:在这项研究中,我们通过鼠模型报告了新设计的近红外荧光染料的体内抗淋巴瘤疗效和诊断潜力,这些近红外荧光染料含有恶性淋巴瘤的小鼠模型,包括一种细胞系衍生的异种移植物(Raji)和两个患者衍生的淋巴瘤异种移植物(VFN-D1和VFN-M2)。合成了两种类型的具有聚合物主链的架构不同的被动靶向缀合物。使用单个直链聚合物链设计了其中一种缀合物,并且第二种缀合物与采用树枝状聚合物芯的星形高分子量(HMW)聚合物更复杂。线性HPMA共聚物通过单点连接与树枝状聚合物核连接,从而形成亲水性聚合物壳。两种聚合物 - 多柔比蛋白缀合物都具有减少副作用的长循环。两种聚合物前药都设计为刺激敏感系统,其中通过pH-不稳定的腙键连接抗癌药物多柔比星。这种聚合物前药在pH7.4的水溶液中相当稳定,通过腙键的水解,在pH5-6.5的pH5-6.5下容易地释放该药物。此外,聚合物用近红外荧光染料标记,使得在体内可视化中长期实现。恶性淋巴瘤代表了最常见的血液恶性肿瘤。大多数恶性淋巴瘤的治疗包括基于蒽环素的多发性化疗组成,最突出的副作用是心脏毒性。与所有测试模型中的同样有毒的常规(未结合)多柔比星相比,我们已经证明了聚合物 - 多柔比星缀合物的显着抗淋巴瘤疗效。观察到携带药物和标记的聚合物载体的有利药代动力学,显示出在肿瘤质量中的药物和聚合物本身的主要吸收。此外,我们已经观察到了很有希望的

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号